What podcasts say about Bret Bostwick
Every statement, with the speaker, the exact quote and the moment it was said.
What Bret Bostwick has said on podcasts
21 statements · 9 positive · 9 negative · 3 neutral
Genetically validated targets can reduce pharmacology’s traditional failure rate.
“it really is a way of changing what is a traditionally 90% failure rate in our field of pharmacology into a much lower rate of failure.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 7:37
APOE E4 homozygotes have ten- to twenty-fold higher Alzheimer’s disease rates.
“individuals that are E4. E4 homozygous have, you know, a 10 to 20 fold higher rate of Alzheimer's disease.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 10:05
Human genetic evidence lowers clinical-trial risk for genetically validated targets.
“these targets have less risks as we go into clinical trials because we've already learned some of what modifying that target will do based on the natural experiments that have happened in human genetics.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 11:05
Oligonucleotide therapies, especially siRNA, are among the best CNS modalities.
“So, yes, I'm a huge bull behind, you know, oligonucleotide therapies, siRNA, I think being one of the best, but also, you know, editing at the DNA level as well.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 16:39
Identifying CNS drug targets is not the primary development obstacle.
“I do not think that understanding what the target is the primary obstacle in the cns”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 17:42
The blood-brain barrier excludes most designed drugs from the brain.
“The blood, brain,”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 18:34
Breyer Capital does not restrict CNS investments to a particular modality.
“we're very modality agnostic at Briar Capital.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 23:23
Breyer Capital has no dedicated psychedelic-medicine investment thesis.
“We do not have a particular thesis on it.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 24:34
Breyer Capital seeks high-risk technologies capable of changing disease treatment paradigms.
“we're really trying to find breakthroughs. We're trying to back high risk breakthrough technology that can paradigm shift the way doctors approach a particular disease area.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 26:59
Breyer Capital operates as an evergreen fund and remains patient with portfolio companies.
“we don't have any particular fund cycle. We're an evergreen fund and we continue to stick with our companies and we can be patient.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 28:31
Mouse data poorly predicts clinical success, whereas human genetics provides stronger guidance.
“mice lie. They lie. They're not a very good proxy for what will work in clinic. Human genetics doesn't lie, right?”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 30:00
Preclinical companies should pursue the fastest credible path to first-in-human trials.
“chart the quickest path, the fastest, most agile path you can to get to clinical trial, that first in-human trial.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 30:18
China has become a global hub for cutting-edge drug development.
“The Chinese biotech system has matured tremendously in just the last few years. And it's now like a hub, a global hub for drug development, cutting edge drug development.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 33:42
U.S. biotechs copying China’s lower-cost model will struggle.
“if you're a US biotech company today and you are going to try to run the same playbook as a Chinese biotech, but do it cheaper, if that's your business strategy, that's going to be tough.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 36:43
Copycat strategies are unlikely to succeed for U.S. biotech companies.
“No copycat strategy because that's just not likely to succeed.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 37:38
Drug development, rather than discovery, is biotech’s primary difficulty.
“drug discovery is easy. It's easy to discover drugs. We have known pathways. What is really hard is drug development.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 39:31
AI has not yet meaningfully shortened biomedical development timelines.
“we really haven't seen AI in a meaningful way come in and compress biomedical timelines.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 39:52
Testing whether a molecule can pass Phase 1 may cost ten to twenty million dollars.
“it's still going to cost probably $10 to $20 million per molecule to figure out whether you can even get through phase one”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 40:14
Clinical AI systems should require human verification.
“there needs to be thoughtful systems in place where there's a necessary human in the loop for verification.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 42:54
Transferrin-receptor shuttles will solve brain delivery only for a small subset of applications.
“I think that that will only be a solution for a very small subset of where we want to deliver in the brain”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 43:58
In vivo drug manufacturing using mRNA technology will be transformative.
“we think that this is going to be transformative.”
Open the episode · Investing In Tomorrow's CNS Breakthroughs With Breyer Capital's Bret Bostwick, M.D.Listen at 45:16
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.